BioCatalystWatch
VSTMWorkspace / VSTM / OverviewCompany library
Price
Market cap
Next catalystDec 5, 2026VS-7375 — TARGET-D 101 · Phase 1/2 dataCompany release ↗
Cash

Chart & Events

Candle interval

Core Clinical

Avutometinib + defactinib — RAMP 301

RAF × MEK × FAK

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

RAF × MEK × FAK

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

KRAS G12D

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

KRAS G12D

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Technology Summary

Scientific context

Detailed technology interpretation

Technology advantages

Representative pipeline applications

Disease and market context

Detailed science focus

Background, answer, next evidence

Clinical

Upcoming clinical milestones

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

PreINDP1P2P3FilingApproved
Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

KRAS G12D

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

KRAS G12D

Upcoming / outlook

  • Timing and evidence

  • Timing and evidence

  • Timing and evidence

Other pipelines

VS-4718

FAK × PYK2

PreINDP1P2P3FilingApproved

Partner / License out

PI3Kδ × PI3Kγ

PreINDP1P2P3FilingApproved

PI3Kδ × PI3Kγ

Approved

PreINDP1P2P3FilingApproved

PI3Kδ × PI3Kγ

Approved

PreINDP1P2P3FilingApproved

Approved / commercial

RAF × MEK × FAK

Approved

PreINDP1P2P3FilingApproved

History / paused

MEK × ARAF × BRAF × CRAF

PreINDP1P2P3FilingApproved

MEK × ARAF × BRAF × CRAF

PreINDP1P2P3FilingApproved

Financial position

Net operating cash flow

Source and basis

Company funding outlook

Upcoming milestones

Financial history

Amounts and sources
PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing



PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing




PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

PeriodCashCurrent investmentsOperatingInvestingFinancing

Source

Annual trends

Reported item

Reported shares and borrowings

Source and basis

Source and basis

Ownership and institutions

Status

Market Reaction / Supply Context

Market Structure

VSTM SEC archive